Precision BioSciences, Inc.
NEWS
Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Precision BioSciences closed on an oversubscribed Series B financing worth $110 million. The funds will be used to continue developing its ARCUS genome editing platform.
JOBS
IN THE PRESS